| Literature DB >> 19022320 |
Tino F Schwarz1, Marek Spaczynski, Achim Schneider, Jacek Wysocki, Andrzej Galaj, Pamela Perona, Sylviane Poncelet, Toufik Zahaf, Karin Hardt, Dominique Descamps, Gary Dubin.
Abstract
The immunogenicity and safety of an HPV-16/18 AS04-adjuvanted vaccine were assessed in women aged 26-55 years and compared with women aged 15-25 years in a Phase III, non-randomised, open-label, age-stratified study. Overall the vaccine was well tolerated and 100% seropositivity was achieved 1 month after the third dose in all age groups. There was a high correlation between HPV-16 and HPV-18 antibody levels (IgG) in cervicovaginal secretions and sera, regardless of age. The HPV-16/18 AS04-adjuvanted vaccine induces a robust and persistent immune response in women >26 years of age and generates antibodies that transudate through the cervix epithelium.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19022320 DOI： 10.1016/j.vaccine.2008.10.088
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641